Krystal Biotech Statistics
Total Valuation
Krystal Biotech has a market cap or net worth of $4.32 billion. The enterprise value is $3.51 billion.
| Market Cap | 4.32B |
| Enterprise Value | 3.51B |
Important Dates
The last earnings date was Monday, August 4, 2025, before market open.
| Earnings Date | Aug 4, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Krystal Biotech has 28.94 million shares outstanding. The number of shares has increased by 1.66% in one year.
| Current Share Class | 28.94M |
| Shares Outstanding | 28.94M |
| Shares Change (YoY) | +1.66% |
| Shares Change (QoQ) | -0.41% |
| Owned by Insiders (%) | 11.20% |
| Owned by Institutions (%) | 87.15% |
| Float | 22.91M |
Valuation Ratios
The trailing PE ratio is 30.45 and the forward PE ratio is 23.13.
| PE Ratio | 30.45 |
| Forward PE | 23.13 |
| PS Ratio | 11.97 |
| Forward PS | 8.40 |
| PB Ratio | 4.15 |
| P/TBV Ratio | 4.15 |
| P/FCF Ratio | 23.31 |
| P/OCF Ratio | 22.12 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 22.93, with an EV/FCF ratio of 18.93.
| EV / Earnings | 23.93 |
| EV / Sales | 9.78 |
| EV / EBITDA | 22.93 |
| EV / EBIT | 23.13 |
| EV / FCF | 18.93 |
Financial Position
The company has a current ratio of 9.68, with a Debt / Equity ratio of 0.01.
| Current Ratio | 9.68 |
| Quick Ratio | 9.13 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | 0.06 |
| Debt / FCF | 0.05 |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is 15.61% and return on invested capital (ROIC) is 10.00%.
| Return on Equity (ROE) | 15.61% |
| Return on Assets (ROA) | 9.23% |
| Return on Invested Capital (ROIC) | 10.00% |
| Return on Capital Employed (ROCE) | 14.44% |
| Revenue Per Employee | $1.31M |
| Profits Per Employee | $533,545 |
| Employee Count | 275 |
| Asset Turnover | 0.35 |
| Inventory Turnover | 1.10 |
Taxes
In the past 12 months, Krystal Biotech has paid $22.03 million in taxes.
| Income Tax | 22.03M |
| Effective Tax Rate | 13.05% |
Stock Price Statistics
The stock price has decreased by -19.01% in the last 52 weeks. The beta is 0.70, so Krystal Biotech's price volatility has been lower than the market average.
| Beta (5Y) | 0.70 |
| 52-Week Price Change | -19.01% |
| 50-Day Moving Average | 142.54 |
| 200-Day Moving Average | 160.40 |
| Relative Strength Index (RSI) | 55.54 |
| Average Volume (20 Days) | 431,090 |
Short Selling Information
The latest short interest is 3.40 million, so 11.74% of the outstanding shares have been sold short.
| Short Interest | 3.40M |
| Short Previous Month | 3.14M |
| Short % of Shares Out | 11.74% |
| Short % of Float | 14.83% |
| Short Ratio (days to cover) | 11.72 |
Income Statement
In the last 12 months, Krystal Biotech had revenue of $359.21 million and earned $146.73 million in profits. Earnings per share was $4.91.
| Revenue | 359.21M |
| Gross Profit | 335.38M |
| Operating Income | 151.80M |
| Pretax Income | 108.38M |
| Net Income | 146.73M |
| EBITDA | 153.16M |
| EBIT | 151.80M |
| Earnings Per Share (EPS) | $4.91 |
Balance Sheet
The company has $681.99 million in cash and $9.68 million in debt, giving a net cash position of $811.11 million or $28.02 per share.
| Cash & Cash Equivalents | 681.99M |
| Total Debt | 9.68M |
| Net Cash | 811.11M |
| Net Cash Per Share | $28.02 |
| Equity (Book Value) | 1.04B |
| Book Value Per Share | 35.97 |
| Working Capital | 754.45M |
Cash Flow
In the last 12 months, operating cash flow was $195.40 million and capital expenditures -$9.96 million, giving a free cash flow of $185.44 million.
| Operating Cash Flow | 195.40M |
| Capital Expenditures | -9.96M |
| Free Cash Flow | 185.44M |
| FCF Per Share | $6.41 |
Margins
Gross margin is 93.37%, with operating and profit margins of 42.26% and 40.85%.
| Gross Margin | 93.37% |
| Operating Margin | 42.26% |
| Pretax Margin | 46.98% |
| Profit Margin | 40.85% |
| EBITDA Margin | 42.64% |
| EBIT Margin | 42.26% |
| FCF Margin | 51.63% |
Dividends & Yields
Krystal Biotech does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -1.66% |
| Shareholder Yield | -1.66% |
| Earnings Yield | 3.39% |
| FCF Yield | 4.29% |
Analyst Forecast
The average price target for Krystal Biotech is $205.27, which is 37.43% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $205.27 |
| Price Target Difference | 37.43% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 11 |
| Revenue Growth Forecast (5Y) | 34.57% |
| EPS Growth Forecast (5Y) | 56.72% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | |
| Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Krystal Biotech has an Altman Z-Score of 31.71 and a Piotroski F-Score of 7.
| Altman Z-Score | 31.71 |
| Piotroski F-Score | 7 |